title: Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors.
abstract: G protein-coupled receptors (GPCRs) are key regulators of cell physiology and control processes ranging from glucose homeostasis to contractility of the heart. A major mechanism for the desensitization of activated GPCRs is their phosphorylation by GPCR kinases (GRKs). Overexpression of GRK2 is strongly linked to heart failure, and GRK2 has long been considered a pharmaceutical target for the treatment of cardiovascular disease. Several lead compounds developed by Takeda Pharmaceuticals show high selectivity for GRK2 and therapeutic potential for the treatment of heart failure. To understand how these drugs achieve their selectivity, we determined crystal structures of the bovine GRK2-Gβγ complex in the presence of two of these inhibitors. Comparison with the apoGRK2-Gβγ structure demonstrates that the compounds bind in the kinase active site in a manner similar to that of the AGC kinase inhibitor balanol. Both balanol and the Takeda compounds induce a slight closure of the kinase domain, the degree of which correlates with the potencies of the inhibitors. Based on our crystal structures and homology modeling, we identified five amino acids surrounding the inhibitor binding site that we hypothesized could contribute to inhibitor selectivity. However, our results indicate that these residues are not major determinants of selectivity among GRK subfamilies. Rather, selectivity is achieved by the stabilization of a unique inactive conformation of the GRK2 kinase domain.
authors: Life Sciences Institute, University of Michigan, 210 Washtenaw Ave., Room 3425, Ann Arbor, MI 48109, USA. tesmerjj@umich.edu
authors: David M
authors: DM
authors: Thal
authors: Raymond Y
authors: RY
authors: Yeow
authors: Christian
authors: C
authors: Schoenau
authors: Jochen
authors: J
authors: Huber
authors: John J G
authors: JJ
authors: Tesmer
references: J Biol Chem. 1994 Jan 14;269(2):1099-105
references: 8288567
references: Acta Crystallogr D Biol Crystallogr. 2003 May;59(Pt 5):936-9
references: 12777817
references: Biochemistry. 1990 Jul 3;29(26):6276-82
references: 2207073
references: Drug Discov Today. 2007 Aug;12(15-16):622-33
references: 17706543
references: Br J Clin Pharmacol. 1990;30 Suppl 1:3S-12S
references: 2176526
references: Science. 2005 Dec 9;310(5754):1686-90
references: 16339447
references: Receptor. 1993 Spring;3(1):39-55
references: 8394172
references: Science. 2000 Sep 15;289(5486):1938-42
references: 10988075
references: J Biol Chem. 1988 Oct 5;263(28):14067-73
references: 2844754
references: J Biol Chem. 2006 Aug 25;281(34):24818-30
references: 16699172
references: Proteins. 2009;77 Suppl 9:114-22
references: 19768677
references: Methods Enzymol. 1982;81:240-6
references: 6212740
references: Science. 2002 Dec 6;298(5600):1912-34
references: 12471243
references: J Med Chem. 2010 Apr 8;53(7):2681-94
references: 20000735
references: J Biol Chem. 2008 May 16;283(20):14053-62
references: 18339619
references: J Biol Chem. 1989 Apr 25;264(12):6707-10
references: 2468660
references: Biochemistry. 1999 Feb 23;38(8):2367-76
references: 10029530
references: EMBO J. 2010 Oct 6;29(19):3249-59
references: 20729810
references: Arch Pharm (Weinheim). 2010 Apr;343(4):193-206
references: 20336692
references: Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
references: 20057044
references: Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
references: 15299926
references: Biochim Biophys Acta. 2005 Dec 30;1754(1-2):38-49
references: 16269279
references: Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
references: 15272157
references: Q Rev Biophys. 2009 Feb;42(1):1-40
references: 19296866
references: Methods Enzymol. 1997;276:307-26
references: 27754618
references: J Biol Chem. 2009 Jun 19;284(25):17206-17215
references: 19364770
references: J Med Chem. 2005 Jan 13;48(1):163-70
references: 15634010
references: Biochem Pharmacol. 2005 Oct 1;70(7):1001-8
references: 16102734
references: J Med Chem. 2010 Feb 25;53(4):1867-70
references: 20128603
references: Annu Rev Med. 2008;59:429-42
references: 17716025
references: Annu Rev Pharmacol Toxicol. 1998;38:289-319
references: 9597157
references: Chem Biol. 1995 Sep;2(9):601-8
references: 9383464
references: Acta Crystallogr D Biol Crystallogr. 2001 Jan;57(Pt 1):122-33
references: 11134934
references: Science. 2003 May 23;300(5623):1256-62
references: 12764189
references: J Mol Med (Berl). 2009 May;87(5):455-63
references: 19229505
references: Science. 2004 Mar 19;303(5665):1800-5
references: 15031492
references: J Biomol Screen. 2007 Apr;12(3):418-28
references: 17438070
references: Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
references: 15572765
references: J Med Chem. 2002 May 23;45(11):2150-9
references: 12014953
references: Mol Pharmacol. 1999 Aug;56(2):370-6
references: 10419556